Emergency Med

Your Article Summary

See Latest Articles

Sumatriptan (Sumavel DosePro): Needle-free injection of 5-HT1 receptor agonist approved for the acute treatment of migraine and cluster headaches
Formulary , 09/10/09

Sumatriptan is a selective agonist of 5–HT1B and 5–HT1D receptors. It has been suggested that the binding of sumatriptan to these receptors induces vasoconstriction. This needle–free, subcutaneous (SC) injectable formulation of sumatriptan was approved on July 15, 2009, for the acute treatment of migraine attacks with or without aura and for the acute treatment of cluster headache episodes...SC sumatriptan should be self–administered by the patient only to the abdomen or thigh. One unit of this agent (containing sumatriptan 6 mg) should be administered; the maximum recommended dose over 24 hours is 2 doses (units) separated by >=1 hour. The dose should not be administered within 2 inches of the navel. Each unit is for single use only.

Today in Neurology/Neurosurgery...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Stroke treatment with alteplase given 3·0—4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial
The Lancet Neurology, 11/17/09

Safety and Efficacy of IV-TPA for Ischaemic Stroke in Clinical Practice - A Bayesian Analysis
Cerebrovascular Diseases, 10/30/09

See All of Neurology/Neurosurgery

Today in Pain Management...keeping you current

Receive free subspecialty "5-minute updates" via email

Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09

Acute back pain: benefits and risks of current treatments
Current Medical Research and Opinion, 11/19/09

Migraine Chronification - Concept and Risk Factors
Discovery Medicine, 10/27/09

See All of Pain Management